CN118284419A - 治疗创伤后应激障碍的方法 - Google Patents

治疗创伤后应激障碍的方法 Download PDF

Info

Publication number
CN118284419A
CN118284419A CN202280058527.2A CN202280058527A CN118284419A CN 118284419 A CN118284419 A CN 118284419A CN 202280058527 A CN202280058527 A CN 202280058527A CN 118284419 A CN118284419 A CN 118284419A
Authority
CN
China
Prior art keywords
compound
ptsd
treatment
dosage form
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280058527.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·巴布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Inc
Original Assignee
Jazz Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Inc filed Critical Jazz Pharmaceuticals Inc
Publication of CN118284419A publication Critical patent/CN118284419A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280058527.2A 2021-08-04 2022-08-03 治疗创伤后应激障碍的方法 Pending CN118284419A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163229387P 2021-08-04 2021-08-04
US63/229,387 2021-08-04
PCT/US2022/074469 WO2023015206A1 (en) 2021-08-04 2022-08-03 Method of treating posttraumatic stress disorder

Publications (1)

Publication Number Publication Date
CN118284419A true CN118284419A (zh) 2024-07-02

Family

ID=83149040

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280058527.2A Pending CN118284419A (zh) 2021-08-04 2022-08-03 治疗创伤后应激障碍的方法

Country Status (10)

Country Link
US (1) US20240335441A1 (https=)
EP (1) EP4380571A1 (https=)
JP (1) JP2024529022A (https=)
KR (1) KR20240046737A (https=)
CN (1) CN118284419A (https=)
AU (1) AU2022323513A1 (https=)
CA (1) CA3227681A1 (https=)
MX (1) MX2024001673A (https=)
TW (1) TW202320779A (https=)
WO (1) WO2023015206A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011793D1 (de) * 2006-10-18 2011-02-17 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen

Also Published As

Publication number Publication date
WO2023015206A1 (en) 2023-02-09
JP2024529022A (ja) 2024-08-01
MX2024001673A (es) 2024-04-30
CA3227681A1 (en) 2023-02-09
TW202320779A (zh) 2023-06-01
AU2022323513A1 (en) 2024-02-22
KR20240046737A (ko) 2024-04-09
US20240335441A1 (en) 2024-10-10
EP4380571A1 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
US20240245631A1 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
Sperling The consequences of uncontrolled epilepsy
Scharf et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.
US20230093150A1 (en) Changing cognitive function with fenfluramine
Alexopoulos et al. Assessment of late life depression
Hurley et al. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial
Steiner et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder
Hu et al. Effect of intensive self-management education on seizure frequency and quality of life in epilepsy patients with prodromes or precipitating factors
Duggan et al. The use of pharmacological treatments for people with personality disorder: a systematic review of randomized controlled trials
US20210299064A1 (en) Method of treating patients with lennox-gastaut syndrome
CA3062247A1 (en) Methods of treating doose syndrome using fenfluramine
Pozzi et al. Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: Therapy optimization as emerging from an observational study
Baiardini et al. Sleep disturbances in allergic diseases
CN118284419A (zh) 治疗创伤后应激障碍的方法
Lipton et al. Epidemiology, progression, prognosis, and comorbidity of migraine
Modanlo et al. Pharmacologic management of skin-picking disorder: an updated review
Xiao et al. The clinical characteristics and related factors of tremor in patients with epilepsy
Ozyurt et al. Investigating the potential link between bruxism and obsessive-compulsive symptomatology: An exploratory study
Tavajohi et al. Assessment of the efficacy of lisdexamfetamine on fatigue in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled study
Chalmé et al. Venlafaxine treatment is associated with improved mood, but not decreased cocaine self-administration, in depressed people who use cocaine
HK40113588A (en) Methods of treating lennox-gastaut syndrome using fenfluramine
de Coca et al. Anticholinergic Load and Fibromyalgia Treatment Analysis: Guidelines and Drug Alerts
Menchetti et al. Pharmacological treatment of depression in primary care: an updated literature review
din Psychiatry Vitamin Be treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.
Stevens et al. Stimulant medication in children and adolescents

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination